Preview

Научно-практическая ревматология

Расширенный поиск

Псориатический артрит: классификация, клиническая картина, диагностика, лечение

https://doi.org/10.14412/1995-4484-2018-60-69

Полный текст:

Аннотация

Псориатический артрит (ПсА) – хроническое воспалительное заболевание суставов, позвоночника и энтезисов из группы спондилоартритов (СпА), которое обычно наблюдается у больных псориазом (Пс). Диагноз ПсА устанавливается с помощью критериев псориатического артрита (CASPAR). Заболевание является результатом взаимодействий между генетическими, иммунологическими факторами и факторами внешней среды. К основным клиническим проявлениям ПсА относят: периферический артрит, энтезит, дактилит, спондилит. ПсА необходимо дифференцировать с ревматоидным артритом, подагрой, реактивным артритом, остеоартритом, анкилозирующим спондилитом. В связи с тем что ПсА является клинически гетерогенным заболеванием, оценка его активности осуществляется с помощью комплексных индексов, с учетом наличия у больного артрита, энтезита, дактилита, спондилита. Целью лечения ПсА является достижение ремиссии или минимальной активности основных клинических проявлений заболевания, замедление или предупреждение рентгенологического прогрессирования, увеличение продолжительности и качества жизни пациентов, а также снижение риска коморбидных заболеваний, что достигается с помощью широкого спектра препаратов различных классов. Терапию следует выбирать с учетом клинических проявлений ПсА и коморбидных состояний пациентов.

Об авторах

Т. В. Коротаева
ФГБНУ «Научноисследовательский институт ревматологии им. В.А.Насоновой».
Россия

 заведующая лабораторией диагностики и инновационных методов лечения псориатического артрита, доктор медицинских наук. 

Москва.



Ю. Л. Корсакова
ФГБНУ «Научноисследовательский институт ревматологии им. В.А.Насоновой».
Россия

тарший научный сотрудник лаборатории диагностики и инновационных методов лечения псориатического артрита, кандидат медицинских наук.

Москва.



Список литературы

1. Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17:809-12.

2. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42:778-83. doi: 10.1093/rheumatology/keg217

3. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55-78. doi: 10.1016/0049-0172(73)90035-8

4. Zias J, Mitchell P. Psoriatic arthritis in a fifth-century Judean Desert monastery. Am J Phys Anthropol. 1996;101:491-502. doi: 10.1002/(SICI)1096-8644(199612)101:4<491::AIDAJPA4>3.0.CO;2-Z

5. Moll JM, Haslock I, Macrae IF, Wright V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome. Medicine (Baltimore). 1974;53:343-64. doi: 10.1097/00005792-19740900000002

6. Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374:2563-74. doi: 10.1056/NEJMra1406182

7. Taylor WJ, Gladman DD, Helliwell PS, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-73. doi: 10.1002/art.21972

8. Olivieri I, Padula A, D’Angelo S, Cutro MS. Psoriatic arthritis sine psoriasis. J Rheumatol. 2009; Suppl 83:28-9. doi: 10.3899/jrheum.090218

9. Eder L, Haddad A, Rosen CF, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheum. 2016;68:915-23. doi: 10.1002/art.39494

10. Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73:242-8. doi: 10.1016/j.jaad.2015.05.001

11. Чамурлиева МН, Логинова ЕЮ, Коротаева ТВ. Выявляемость псориатического артрита у больных псориазом в дерматологической и ревматологической клинике. Современная ревматология. 2016;10(4):47-50 [Chamurlieva MN, Loginova EYu, Korotaeva TV. Detection rates of psoriatic arthritis in patients with psoriasis in a dermatology and rheumatology clinic. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(4):47-50 (In Russ.)]. doi: 10.14412/1996-7012-2016-4-47-50

12. Michelsen B, Fiane R, Diamantopoulos AP, et al. A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS One. 2015;10(4):e0123582. doi: 10.1371/journal.pone.0123582

13. Kotsis K, Voulgari PV, Tsifetaki N, et al. Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life. Arthritis Care Res (Hoboken). 2012;64:1593-601. doi: 10.1002/acr.21725

14. Tillett W, Shaddick G, Askari A, et al. Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. Rheumatology (Oxford). 2015;54:157-62. doi: 10.1093/rheumatology/keu264

15. Arumugam R, McHugh NJ. Mortality and causes of death in psoriatic arthritis. J Rheumatol. 2012;89 Suppl:32-5. doi: 10.3899/jrheum.120239

16. Buckley C, Cavill C, Taylor G, et al. Mortality in psoriatic arthritis – a singlecenter study from the UK. J Rheumatol. 2010;37:2141-4. doi: 10.3899/jrheum.100034

17. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376:957-70. doi: 10.1056/NEJMra1505557

18. Mease PJ. Psoriatic Arthritis: update on pathophysiology, assessement and management. Ann Rheum Dis. 2011;70 Suppl:77-84. doi: 10.1136/ard.2010.140582

19. Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012;71:1273-7. doi: 10.1136/annrheumdis-2012-201299

20. Коротаева ТВ. Псориатический артрит: клиника, диагностика, патогенез, лечение, маркеры кардиоваскулярного риска. Москва: НПО «Медиа-Графика»; 2013. 309 с. [Korotaeva TV. Psoriaticheskii artrit: klinika, diagnostika, patogenez, lechenie, markery kardiovaskulyarnogo riska [Psoriatic arthritis: clinic, diagnosis, pathogenesis, treatment, markers of cardiovascular risk]. Moscow: NPO «Media-Grafika»; 2013. 309 p.]. ISBN 978-5-905541-02-5.

21. Khan M, Schentag C, Gladman DD. Clinical and radiological changes during psoriatic arthritis disease progression. J Rheumatol. 2003;30:1022-6.

22. Gladman DD, Ziouzina O, Thavaneswaran A, Chandran V. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol. 2013;40:1357-9. doi: 10.3899/jrheum.130163

23. Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis. 2005;64:188-90. doi: 10.1136/ard.2003.018184

24. Kehl AS, Corr M, Weisman MH. Review: enthesitis: new insights into pathogenesis, diagnostic modalities, and treatment. Arthritis Rheum. 2016;68:312-22. doi: 10.1002/art.39458

25. Stoll ML, Zurakowski D, Nigrovic LE, et al. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum. 2006;54:3564-72. doi: 10.1002/art.22173

26. Colbert RA. Classification of juvenile spondyloarthritis: enthesitisrelated arthritis and beyond. Nat Rev Rheumatol. 2010;6:477-85. doi: 10.1038/nrrheum.2010.103

27. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2:14-7. doi: 10.1136/ard.2004.032482

28. Chandran V, Barrett J, Schentag NC, et al. Axial Psoriatic Arthritis: update on a longterm prospective study. J Rheumatol. 2009;36;2744-50. doi: 10.3899/jrheum.090412

29. Sieper J, van der Heijde D, Landewe R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis International Society (ASAS). Ann Rheum Dis. 2009;68:784-8. doi: 10.1136/ard.2008.101501

30. Kane D, Pathare S. Early psoriatic arthritis. Rheum Dis Clin North Am. 2005;31(4):641-57. doi: 10.1016/j.rdc.2005.07.009

31. Qureshi AA, Husni ME, Mody E. Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. Semin Cutan Med Surg. 2005;24:46-51. doi: 10.1016/j.sder.2005.01.006

32. Prey S, Paul C, Bronsard V, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24 Suppl 2:31-5. doi: 10.1111/j.1468-3083.2009.03565.x

33. Gottlieb A, Korman N, Gordon K, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851-64. doi: 10.1016/j.jaad.2008.02.040

34. Mease PJ. Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions. Semin Arthritis Rheum. 2009;38:320-35. doi: 10.1016/j.semarthrit.2008.01.003

35. Raychaudhuri SK, Chatterjee S, Nguyen C, et al. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8:331-4. doi: 10.1089/met.2009.0124

36. Li W-Q, Han J-L, Chan TA. Psoriasis and psoriatic arthritis and increased risk of incedent Crohn's disease in US women. Ann Rheum Dis. 2013 Jul;72(7):1200-5. doi: 10.1136/annrheumdis2012-202143

37. Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015;27:118-26. doi: 10.1097/BOR.0000000000000152

38. Gossec L, Smolen J, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4-12. doi: 10.1136/annrheumdis-2011-200350

39. Mease PJ. Assessment tools in psoriatic arthritis. J Rheumatol. 2008;35:1426-30.

40. Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise – the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol. 2007;34:1740-5.

41. Nell-Duxneuner VP, Stamm TA, Machold KP, et al. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis. 2010;69:546-9. doi: 10.1136/ard.2009.117945

42. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology. 2003;42(2):244-57. doi: 10.1093/rheumatology/keg072

43. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68:1387-94. doi: 10.1136/ard.2008.094946

44. Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2010;70:272-7. doi: 10.1136/ard.2010.129379

45. Helliwell PS, Fitzgerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72:98691. doi: 10.1136/annrheumdis-2012-201341

46. Saber TP, Ng CT, Renard G, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther. 2010;12(3):94-8. doi: 10.1186/ar3021

47. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken). 2010;62:965-9. doi: 10.1002/acr.20155

48. Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol. 2006;33:1417-21.

49. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheum. 2016;68:1060-71. doi: 10.1002/art.39573

50. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499-510. doi: 10.1136/annrheumdis2015-208337

51. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis. 2005;64 Suppl 2:ii74-ii77. doi: 10.1136/ard.2004.030783

52. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51:1368-77. doi: 10.1093/rheumatology/kes001

53. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50:1939-50. doi: 10.1002/art.20253

54. Mease PJ. Biologic therapy for psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:723-38. doi: 10.1016/j.rdc.2015.07.010

55. Weitz JE, Ritchlin CT. Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis. Expert Opin Biol Ther. 2014;14:515-26. doi: 10.1517/14712598.2014.890587

56. McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-ofconcept trial. Ann Rheum Dis. 2014;73:349-56. doi: 10.1136/annrheumdis-2012-202646

57. Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79-87. doi: 10.1136/annrheumdis-2016-209709

58. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020-6. doi: 10.1136/annrheumdis-2013205056

59. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a sixmonth, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63:939-48. doi: 10.1002/art.30176


Для цитирования:


Коротаева Т.В., Корсакова Ю.Л. Псориатический артрит: классификация, клиническая картина, диагностика, лечение. Научно-практическая ревматология. 2018;56(1):60-69. https://doi.org/10.14412/1995-4484-2018-60-69

For citation:


Korotaev T.V., Korsakova Y.I. PSORIATIC ARTHRITIS: CLASSIFICATION, CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT. Rheumatology Science and Practice. 2018;56(1):60-69. (In Russ.) https://doi.org/10.14412/1995-4484-2018-60-69

Просмотров: 2895


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)